×
S&P 500   3,885.92 (+1.06%)
DOW   31,296.66 (+0.83%)
QQQ   292.13 (+1.15%)
AAPL   144.79 (+1.31%)
MSFT   266.39 (+0.07%)
META   170.24 (+0.28%)
GOOGL   2,323.01 (+1.38%)
AMZN   114.89 (+0.49%)
TSLA   714.71 (+2.81%)
NVDA   156.26 (+3.28%)
NIO   22.90 (+9.94%)
BABA   123.76 (+3.90%)
AMD   78.41 (+4.06%)
MU   58.58 (+2.11%)
CGC   2.67 (+0.75%)
T   21.09 (+0.33%)
GE   62.92 (+2.19%)
F   11.51 (+4.07%)
DIS   97.01 (+0.97%)
AMC   12.82 (+1.99%)
PFE   53.24 (+0.93%)
PYPL   73.94 (+0.96%)
NFLX   187.16 (+1.68%)
S&P 500   3,885.92 (+1.06%)
DOW   31,296.66 (+0.83%)
QQQ   292.13 (+1.15%)
AAPL   144.79 (+1.31%)
MSFT   266.39 (+0.07%)
META   170.24 (+0.28%)
GOOGL   2,323.01 (+1.38%)
AMZN   114.89 (+0.49%)
TSLA   714.71 (+2.81%)
NVDA   156.26 (+3.28%)
NIO   22.90 (+9.94%)
BABA   123.76 (+3.90%)
AMD   78.41 (+4.06%)
MU   58.58 (+2.11%)
CGC   2.67 (+0.75%)
T   21.09 (+0.33%)
GE   62.92 (+2.19%)
F   11.51 (+4.07%)
DIS   97.01 (+0.97%)
AMC   12.82 (+1.99%)
PFE   53.24 (+0.93%)
PYPL   73.94 (+0.96%)
NFLX   187.16 (+1.68%)
S&P 500   3,885.92 (+1.06%)
DOW   31,296.66 (+0.83%)
QQQ   292.13 (+1.15%)
AAPL   144.79 (+1.31%)
MSFT   266.39 (+0.07%)
META   170.24 (+0.28%)
GOOGL   2,323.01 (+1.38%)
AMZN   114.89 (+0.49%)
TSLA   714.71 (+2.81%)
NVDA   156.26 (+3.28%)
NIO   22.90 (+9.94%)
BABA   123.76 (+3.90%)
AMD   78.41 (+4.06%)
MU   58.58 (+2.11%)
CGC   2.67 (+0.75%)
T   21.09 (+0.33%)
GE   62.92 (+2.19%)
F   11.51 (+4.07%)
DIS   97.01 (+0.97%)
AMC   12.82 (+1.99%)
PFE   53.24 (+0.93%)
PYPL   73.94 (+0.96%)
NFLX   187.16 (+1.68%)
S&P 500   3,885.92 (+1.06%)
DOW   31,296.66 (+0.83%)
QQQ   292.13 (+1.15%)
AAPL   144.79 (+1.31%)
MSFT   266.39 (+0.07%)
META   170.24 (+0.28%)
GOOGL   2,323.01 (+1.38%)
AMZN   114.89 (+0.49%)
TSLA   714.71 (+2.81%)
NVDA   156.26 (+3.28%)
NIO   22.90 (+9.94%)
BABA   123.76 (+3.90%)
AMD   78.41 (+4.06%)
MU   58.58 (+2.11%)
CGC   2.67 (+0.75%)
T   21.09 (+0.33%)
GE   62.92 (+2.19%)
F   11.51 (+4.07%)
DIS   97.01 (+0.97%)
AMC   12.82 (+1.99%)
PFE   53.24 (+0.93%)
PYPL   73.94 (+0.96%)
NFLX   187.16 (+1.68%)
NASDAQ:XENE

Xenon Pharmaceuticals Stock Forecast, Price & News

$33.31
+1.71 (+5.41%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$31.60
$34.06
50-Day Range
$25.44
$34.70
52-Week Range
$14.65
$36.42
Volume
913,939 shs
Average Volume
611,476 shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.40

Xenon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
30.3% Upside
$43.40 Price Target
Short Interest
Healthy
4.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.11mentions of Xenon Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.08) to ($3.19) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.51 out of 5 stars

Medical Sector

984th out of 1,433 stocks

Pharmaceutical Preparations Industry

486th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Xenon Pharmaceuticals logo

About Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE Stock News Headlines

Xenon Pharmaceuticals (NASDAQ:XENE) PT Lowered to $41.00
Xenon Pharmaceuticals Tops Q1 EPS by 6c
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENE
Employees
149
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/07/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$43.40
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+30.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-78,880,000.00
Net Margins
-360.80%
Pretax Margin
-363.84%

Debt

Sales & Book Value

Annual Sales
$18.44 million
Book Value
$10.51 per share

Miscellaneous

Free Float
49,888,000
Market Cap
$1.77 billion
Optionable
Optionable
Beta
1.58














Xenon Pharmaceuticals Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals
or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price forecast for 2022?

6 equities research analysts have issued 12 month price targets for Xenon Pharmaceuticals' stock. Their XENE stock forecasts range from $40.00 to $48.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $43.40 in the next year. This suggests a possible upside of 30.3% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Xenon Pharmaceuticals' stock performed in 2022?

Xenon Pharmaceuticals' stock was trading at $31.24 at the start of the year. Since then, XENE stock has increased by 6.6% and is now trading at $33.31.
View the best growth stocks for 2022 here
.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Xenon Pharmaceuticals
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.03. The biopharmaceutical company had revenue of $8.77 million for the quarter, compared to analysts' expectations of $9.22 million. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 20.94% and a negative net margin of 360.80%. During the same period in the prior year, the company earned ($0.42) earnings per share.
View Xenon Pharmaceuticals' earnings history
.

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:
  • Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director (Age 46, Pay $957.16k)
  • Ms. Sherry Aulin, Chief Financial Officer (Age 38, Pay $458.64k)
  • Dr. Christopher John Kenney M.D., Chief Medical Officer (Age 51, Pay $494.83k) (LinkedIn Profile)
  • Ms. Jodi Regts M.B.A., B.A., MBA, VP of Corp. Affairs & Investor Relations
  • Ms. Shelley McCloskey B.A., Sr. VP of HR (Age 62)
  • Dr. Robin P. Sherrington Ph.D., Exec. VP of Strategy & Innovation (Age 61)
  • Dr. James R. Empfield Ph.D., Exec. VP of Drug Discovery (Age 61)
  • Ms. Sheila M. Grant M.B.A., M.Sc., MBA, Sr. VP of R&D Operations
  • Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer (Age 43)
  • Dr. Kenneth Sommerville, Interim Chief Medical Officer

What other stocks do shareholders of Xenon Pharmaceuticals own?

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $33.31.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $1.77 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78,880,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals employs 149 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for Xenon Pharmaceuticals is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.

This page (NASDAQ:XENE) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.